These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10449124)

  • 21. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
    Sima AA; Nathaniel V; Prashar A; Bril V; Greene DA
    Diabetes; 1991 Sep; 40(9):1090-9. PubMed ID: 1936616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats.
    Nishikawa M; Yoshida K; Okamoto M; Itoh Y; Kohsaka M
    J Antibiot (Tokyo); 1991 Apr; 44(4):441-4. PubMed ID: 1903376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials of sorbinil on nerve function.
    Pfeifer MA
    Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
    Chalk C; Benstead TJ; Moore F
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD004572. PubMed ID: 17943821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.
    van Gerven JM
    Diabet Med; 1993; 10 Suppl 2():35S-38S. PubMed ID: 8334839
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
    Satoh J; Kohara N; Sekiguchi K; Yamaguchi Y
    J Diabetes Res; 2016; 2016():5383797. PubMed ID: 26881251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy.
    Dyck PJ; Zimmerman BR; Vilen TH; Minnerath SR; Karnes JL; Yao JK; Poduslo JF
    N Engl J Med; 1988 Sep; 319(9):542-8. PubMed ID: 3136330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
    Yagihashi S; Yamagishi SI; Wada Ri R; Baba M; Hohman TC; Yabe-Nishimura C; Kokai Y
    Brain; 2001 Dec; 124(Pt 12):2448-58. PubMed ID: 11701599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
    Sundkvist G; Lilja B; Rosén I; Agardh CD
    Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 40. Structure-function interactions in the therapeutic response of diabetic neuropathy.
    Sima AA
    J Diabetes Complications; 1992; 6(1):64-8. PubMed ID: 1562761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.